vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and YORK WATER CO (YORW). Click either name above to swap in a different company.
YORK WATER CO is the larger business by last-quarter revenue ($19.4M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). YORK WATER CO runs the higher net margin — 26.7% vs -0.8%, a 27.5% gap on every dollar of revenue. On growth, YORK WATER CO posted the faster year-over-year revenue change (3.2% vs -25.7%). Over the past eight quarters, YORK WATER CO's revenue compounded faster (5.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
The York Water Company is an investor-owned, public utility company based in York, Pennsylvania and operating throughout Pennsylvania. The company was founded in 1816 by a group of local businessmen concerned about fire protection.
CTMX vs YORW — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $19.4M |
| Net Profit | $-154.0K | $5.2M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 33.2% |
| Net Margin | -0.8% | 26.7% |
| Revenue YoY | -25.7% | 3.2% |
| Net Profit YoY | 97.6% | 0.5% |
| EPS (diluted) | — | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $19.4M | ||
| Q3 25 | — | $20.2M | ||
| Q2 25 | $18.7M | $19.1M | ||
| Q1 25 | $50.9M | $18.3M | ||
| Q4 24 | $38.1M | $18.8M | ||
| Q3 24 | $33.4M | $19.6M | ||
| Q2 24 | $25.1M | $18.6M | ||
| Q1 24 | $41.5M | $17.5M |
| Q4 25 | — | $5.2M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | $-154.0K | $5.1M | ||
| Q1 25 | $23.5M | $3.6M | ||
| Q4 24 | $18.9M | $5.1M | ||
| Q3 24 | $5.7M | $5.9M | ||
| Q2 24 | $-6.5M | $5.0M | ||
| Q1 24 | $13.8M | $4.3M |
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 39.1% | ||
| Q2 25 | -6.9% | 37.1% | ||
| Q1 25 | 44.4% | 34.3% | ||
| Q4 24 | 46.4% | 35.8% | ||
| Q3 24 | 12.3% | 41.1% | ||
| Q2 24 | -33.7% | 37.9% | ||
| Q1 24 | 28.1% | 35.5% |
| Q4 25 | — | 26.7% | ||
| Q3 25 | — | 30.6% | ||
| Q2 25 | -0.8% | 26.5% | ||
| Q1 25 | 46.2% | 19.8% | ||
| Q4 24 | 49.6% | 27.4% | ||
| Q3 24 | 17.2% | 29.9% | ||
| Q2 24 | -26.0% | 26.8% | ||
| Q1 24 | 33.3% | 24.7% |
| Q4 25 | — | $0.36 | ||
| Q3 25 | — | $0.43 | ||
| Q2 25 | — | $0.35 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | — | $0.35 | ||
| Q1 24 | — | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $1.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $240.3M |
| Total Assets | $175.1M | $680.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.0K | ||
| Q3 25 | — | $1.0K | ||
| Q2 25 | $49.0M | $1.0K | ||
| Q1 25 | $47.6M | $1.0K | ||
| Q4 24 | $38.1M | $1.0K | ||
| Q3 24 | $40.6M | $1.0K | ||
| Q2 24 | $43.2M | $1.0K | ||
| Q1 24 | $36.2M | $3.3M |
| Q4 25 | — | $240.3M | ||
| Q3 25 | — | $238.0M | ||
| Q2 25 | $119.9M | $234.6M | ||
| Q1 25 | $25.0M | $232.1M | ||
| Q4 24 | $-456.0K | $231.2M | ||
| Q3 24 | $-23.5M | $228.7M | ||
| Q2 24 | $-31.2M | $225.4M | ||
| Q1 24 | $-31.7M | $222.9M |
| Q4 25 | — | $680.9M | ||
| Q3 25 | — | $667.1M | ||
| Q2 25 | $175.1M | $653.7M | ||
| Q1 25 | $98.5M | $641.8M | ||
| Q4 24 | $120.5M | $633.5M | ||
| Q3 24 | $139.0M | $621.4M | ||
| Q2 24 | $159.2M | $610.4M | ||
| Q1 24 | $184.7M | $602.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $8.4M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 1.63× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.4M | ||
| Q3 25 | — | $7.8M | ||
| Q2 25 | $-15.8M | $7.6M | ||
| Q1 25 | $-21.0M | $6.0M | ||
| Q4 24 | $-19.9M | $10.2M | ||
| Q3 24 | $-20.7M | $7.5M | ||
| Q2 24 | $-19.5M | $6.7M | ||
| Q1 24 | $-26.0M | $6.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 1.63× | ||
| Q3 25 | — | 1.26× | ||
| Q2 25 | — | 1.50× | ||
| Q1 25 | -0.89× | 1.65× | ||
| Q4 24 | -1.05× | 1.98× | ||
| Q3 24 | -3.61× | 1.29× | ||
| Q2 24 | — | 1.34× | ||
| Q1 24 | -1.89× | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
YORW
Segment breakdown not available.
